• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Why prescribe highly purified factor VIII and IX concentrates?

作者信息

Berntorp E

机构信息

Department for Coagulation Disorders, Malmö University Hospital, Sweden.

出版信息

Vox Sang. 1996;70(2):61-8. doi: 10.1111/j.1423-0410.1996.tb01295.x.

DOI:10.1111/j.1423-0410.1996.tb01295.x
PMID:8801765
Abstract

The aftermath of the HIV catastrophe and hepatitis virus transmission to hemophiliacs has been characterized by continuous efforts to improve the purity of factor VIII and factor IX concentrates, increasing sophistication of the virucidal methods used, and the introduction of recombinant factor VIII. The cost of hemophilia care is substantial and there is a large price difference between products depending on their purity; generally, the purer the concentrate, the higher the price. The use of expensive highly purified concentrates may be questioned if these products are not superior in terms of safety, efficacy or convenience. The properties of concentrates used in hemophilia care are discussed in this review, as are their safety and side effects. The available data do not clearly reveal any clinical difference between factor VIII concentrates, although the highly purified products may be of theoretical benefit. With regard to factor IX, purified products do not seem to carry any risk of the well-known thromboembolic complications which occur in certain situations after treatment with prothrombin complex concentrates.

摘要

相似文献

1
Why prescribe highly purified factor VIII and IX concentrates?
Vox Sang. 1996;70(2):61-8. doi: 10.1111/j.1423-0410.1996.tb01295.x.
2
Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.血友病和血管性血友病:2. 管理。加拿大血友病诊所主任协会
CMAJ. 1995 Jul 15;153(2):147-57.
3
[Transmission of hepatitis C by factor concentrates].
Sangre (Barc). 1996 Apr;41(2):160-1.
4
Has hepatitis A virus been transmitted by clotting factor concentrates among hemophiliacs in the United States?
Vox Sang. 1994;67 Suppl 4:12-5; discussion 24-6.
5
Purity of concentrates for substitution therapy: acceptable and undesirable contaminants--Madrid 1978.
Scand J Haematol Suppl. 1980;35:65-89.
6
Recombinant factor VIII in hemophilia A: the Canadian experience.
Blood Coagul Fibrinolysis. 1997 Aug;8 Suppl 1:S33-9.
7
Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III.
Med J Aust. 1985 Jul 8;143(1):11-3. doi: 10.5694/j.1326-5377.1985.tb122758.x.
8
Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
Dev Biol Stand. 1987;67:303-10.
9
Therapeutic properties and safety of recombinant factor VIII and factor IX.重组凝血因子 VIII 和凝血因子 IX 的治疗特性与安全性。
Pol Arch Med Wewn. 2009 Jun;119(6):403-9.
10
Antibody to hepatitis C (anti C 100-3) in French hemophiliacs.法国血友病患者中的丙型肝炎抗体(抗C 100-3)
Nouv Rev Fr Hematol (1978). 1991;33(3):263-6.

引用本文的文献

1
Advances in biopharmaceutical products for hemophilia.用于血友病的生物制药产品的进展。
iScience. 2024 Dec 3;27(12):111436. doi: 10.1016/j.isci.2024.111436. eCollection 2024 Dec 20.
2
Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies.基因疗法可能不像人们想象的那么昂贵:评估单次和短期疗法价值的挑战。
J Manag Care Spec Pharm. 2021 May;27(5):674-681. doi: 10.18553/jmcp.2021.27.5.674.